Physician profile
Amber Boyd
NPI 1407005085
$1,344.97
in general payments reported to CMS, 2019-2025
22 companies · $259 in 2025
The $259 reported for 2025 was more than what 81% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $137 · 2023: $320 · 2024: $169 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $307.68 | 2021-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $132.49 | 2021-2025 | Bexsero, Penmenvy |
| Ironshore Pharmaceuticals INC. | $107.81 | 2023-2024 | Jornay Pm |
| Amgen INC. | $101.42 | 2021-2023 | Otezla, Repatha |
| Pfizer INC. | $87.44 | 2023-2025 | |
| Cranial Technologies, INC | $65.16 | 2023 | Doc Band |
| Collegium Pharmaceutical, INC. | $63.36 | 2025 | Jornay Pm |
| Corium, LLC | $59.27 | 2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $54.04 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $47.92 | 2024 | Ycanth |
| Abbvie INC. | $44.78 | 2021-2023 | |
| Astellas Pharma US INC | $40.90 | 2023 | Veozah |
| Supernus Pharmaceuticals, INC. | $35.19 | 2021 | |
| Vertical Pharmaceuticals, LLC | $32.11 | 2025 | Relexxii |
| Lilly USA, LLC | $30.32 | 2021-2024 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $29.12 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.83 | 2021 | |
| Ambu INC. | $22.31 | 2022 | |
| Amarin Pharma, INC. | $19.98 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.81 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.24 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.